NCT04541082
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
StatusActive, Not Recruiting
PhasePhase 1
SponsorJazz Pharmaceuticals
Primary completion (estimated)
At risk: Primary completion moved at least 8 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 15 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Final enrollment: 35 participants (planned 102)
- Site details revised
Notable Primary completion pushed from Jul 2026 to Mar 31, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 61 words
- Study completion pushed from Dec 2026 to Sep 30, 2027
- Study description shortened, about 19 words
- Publications: details revised at 1 of 1 entry
- Notable Primary completion date: Dec 2025 to Jul 2026v15
- Minor Site contact updatedv14
- Notable Primary completion date: Sep 2024 to Dec 2025
- Study completion date: Feb 2025 to Dec 2026
- Site contact updated
Show 9 earlier versionsHide 9 earlier versions
- Notable Eligibility criteria expanded, about 3 wordsv11
- Notable Eligibility criteria expanded, about 1,109 words
- Primary endpoints: 1 to 2
- Study description expanded, about 813 words
- Notable Eligibility criteria expanded, about 165 words
- Site contact updated
- Notable Lead sponsor: Oncoceutics, Inc. to Jazz Pharmaceuticalsv7
- Minor Start date changed from estimate of Oct 2020 to Oct 26, 2020v6
- Notable Eligibility criteria expanded, about 323 wordsv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Sep 2020 to Oct 2020
- Site details revised
- Minor Trial status: Recruiting to Not Yet Recruiting
- Site details revised
- Minor Study title shortened, about 9 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Maximum Tolerated Dose (MTD) of single-agent, oral ONC206
Timeframe: 28 Days
Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)
Timeframe: 28 Days
Arms and interventions
ONC206Experimental
Drugs: ONC206
Sites
1 site in 1 country
- National Institutes of HealthBethesda, Maryland, United States